Browse the evidence

Caloric restriction improves insulin sensitivity and reduces fasting insulin, but has a minor or non-significant impact on fasting glucose levels in balanced groups.

Caloric restriction lowers insulin levels, which improves insulin sensitivity. However, it may not significantly lower fasting blood glucose unless the study groups were balanced at baseline.

Time-restricted eating (TRE) significantly reduces diastolic blood pressure (DBP) in adults with obesity, but does not significantly affect systolic blood pressure (SBP).

If you have high blood pressure, TRE might help lower your diastolic (bottom) number, but don't expect it to significantly change your systolic (top) number. This is a secondary benefit to weight loss, not a primary treatment for hypertension.

Intermittent Fasting improves metabolic health markers, including insulin sensitivity, lipid profiles (reduced triglycerides and LDL), and blood pressure, independent of weight loss magnitude, through mechanisms involving ketone body production and hormonal regulation.

Beyond weight loss, IER can improve your blood lipids and blood pressure. This happens partly because your body switches to burning fat for fuel (ketones) during fasting periods, which improves insulin sensitivity and reduces inflammation. You do not need to lose a massive amount of weight to see these metabolic benefits.

Sulfur amino acid restriction (SAAR) significantly decreases serum leptin levels and increases plasma ketone bodies (beta-hydroxybutyrate and acetoacetate) compared to a control diet, indicating a shift in metabolic fuel usage.

Reducing sulfur amino acids lowers leptin (a hormone that signals fat stores to the brain) and increases ketones. This suggests your body is switching to burning fat for fuel more efficiently, which may help sustain weight loss.

VLCD intervention significantly increases Sex-Hormone-Binding Globulin (SHBG) and reduces fasting blood glucose in obese women with PCOS, whereas moderate energy deficit does not significantly alter these specific metabolic markers over 8 weeks.

VLCDs offer a metabolic advantage over moderate dieting for PCOS patients by significantly boosting SHBG and lowering fasting glucose. This suggests VLCD may be necessary to reverse the underlying insulin resistance driving hyperandrogenism in some patients.

Fasting-based strategies improve insulin sensitivity (reduced fasting insulin and HOMA-IR) in the short term compared to continuous caloric restriction, but this benefit is not sustained in long-term outcomes for fasting glucose.

If you are obese, trying fasting strategies (like time-restricted eating) may help improve your insulin sensitivity in the first few months compared to just counting calories. This is measured by lower fasting insulin levels. However, this doesn't necessarily mean you will lose more weight in the long run, so use this metabolic benefit as one factor in choosing your strategy.

Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).

Intermittent fasting improves total cholesterol and LDL, key markers for heart health. However, be aware that triglycerides may temporarily rise in the first 12 weeks as your body adapts. This is often a transient phase. If you have high baseline triglycerides, consult a healthcare provider and consider longer-term adherence to see the full lipid benefits.

Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.

Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.

A ketogenic diet significantly improves quality of life (QoL) and reduces fatigue symptoms in individuals with overweight, particularly those with high baseline fatigue.

If you are overweight and struggle with fatigue, a ketogenic diet may help boost your energy and overall quality of life. This benefit seems most pronounced if you already feel fatigued. Stick to the diet for at least three months, ensure you are in ketosis, and monitor how your energy levels change.

Reduction in chin subcutaneous adipose tissue (chin-SAT) is independently associated with improvements in glycemic control (fasting glucose, HbA1c, HOMA-IR) and lipid profiles, even after adjusting for changes in visceral adipose tissue (VAT) and waist circumference.

Losing chin fat may be a sign of improving metabolic health, specifically insulin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood sugar control, independent of how much belly fat you lose.

Reduction in cervical subcutaneous adipose tissue (cervical-SAT) is independently associated with improvements in lipid profiles (triglycerides, LDL-C, cholesterol/HDL ratio) and leptin levels, independent of visceral adipose tissue (VAT).

Losing neck fat may be a sign of improving metabolic health, specifically lipid profiles and leptin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood lipid control, independent of how much belly fat you lose.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) achieve 10-15% weight loss and superior metabolic improvements compared to lifestyle changes alone, but are recommended for non-responders or those with comorbidities.

If lifestyle changes alone do not achieve sufficient weight loss or if you have obesity-related comorbidities, discuss GLP-1 receptor agonists (like semaglutide or liraglutide) with your doctor. These medications can lead to 10-15% weight loss and significant metabolic improvements, though they may cause gastrointestinal side effects. They are most effective when combined with lifestyle modifications.

Tirzepatide produces significant weight loss (mean 18.73%) and improves quality of life in overweight or obese adults without diabetes, but significantly increases the risk of adverse events compared to placebo.

Tirzepatide is a highly effective treatment for weight loss in non-diabetic overweight or obese adults, producing an average 18.73% body weight loss. However, it comes with a significantly higher risk of adverse events, particularly gastrointestinal issues, compared to placebo. Patients should be monitored closely for these side effects.

Intermittent fasting downregulates enteroendocrine signaling, specifically GLP-1, GCG, and PYY, while upregulating PPAR-α, which correlates with improved lipid profiles.

The molecular changes observed (PPAR-α upregulation, GLP-1 downregulation) suggest that IF works by altering how your body processes fats and regulates hormones, not just by restricting calories. This may inform future targeted therapies.

Increasing the regularity of meal times (reducing mealtime variability) leads to significant weight loss without the need for calorie restriction or changes in macronutrient composition.

Use a smartphone app to track your meals for two weeks. Identify the specific times you eat most frequently. Then, for the next six weeks, restrict your eating to only those specific times, aiming for a consistency of within 45 minutes of your usual times. Do not worry about changing what or how much you eat. This regularity helps your body's internal clock optimize metabolism, leading to weight loss.

Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.

For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.

Insulin resistance causes dyslipidemia characterized by high triglycerides, low HDL, and small dense LDL, which significantly increases the incidence of cardiovascular disease.

Insulin resistance changes your lipid profile in a dangerous way: high triglycerides, low HDL, and small dense LDL. This specific combination is highly atherogenic. Managing insulin sensitivity is key to improving this profile.

Dietary fiber fermentation by gut microbiota produces short-chain fatty acids (SCFAs) which stimulate the secretion of gut peptides (GLP-1, PYY) via GPR41/GPR43 receptors, thereby improving glucose regulation and reducing energy intake.

To leverage your gut microbiome for better blood sugar control and appetite regulation, consume complex carbohydrates (dietary fibers) that resist digestion in the small intestine. These fibers reach the colon where bacteria ferment them into short-chain fatty acids (SCFAs). These SCFAs activate specific receptors (GPR41/43) on gut cells, triggering the release of hormones like GLP-1 and PYY that improve glucose handling and reduce hunger. Focus on sources like resistant starches and arabinoxylans.

Chronic low-grade inflammation is a causative mechanism for insulin resistance and metabolic disease in obesity, rather than merely a consequence.

If you are overweight, your body may be in a state of chronic, low-grade inflammation that actively interferes with how your cells respond to insulin. This isn't just 'being fat'; it's a biological shift that promotes metabolic disease. Addressing this requires looking beyond simple calorie counting to strategies that may reduce this inflammatory burden, such as improving diet quality and managing stress, as the inflammation itself drives insulin resistance.

Subcutaneous semaglutide at 0.4 mg daily significantly improves histologic resolution of NASH without worsening fibrosis in patients with stage F2 or F3 fibrosis compared to placebo.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks significantly increases the likelihood of NASH resolution without worsening fibrosis compared to placebo. This benefit comes with a higher risk of gastrointestinal side effects, particularly nausea, which often diminishes over time. Patients should be counseled on nutrition and physical activity alongside this treatment.

Sleep disruption (fragmentation/continuity loss) causes increased sympathetic nervous system activity and HPA axis activation, leading to short-term stress responsivity and long-term cardiovascular disease risk.

Prioritize sleep continuity, not just duration. If you wake up frequently, your body experiences a stress response similar to being awake, increasing long-term risks for heart disease and high blood pressure. Focus on strategies to maintain uninterrupted sleep, such as managing environmental factors (light/noise) and addressing underlying sleep disorders like apnea.

Sleep disruption leads to metabolic dysregulation (decreased insulin sensitivity, altered leptin/ghrelin) increasing the risk of obesity, metabolic syndrome, and type 2 diabetes.

Poor sleep disrupts the hormones that control hunger (ghrelin increases, leptin decreases) and reduces your body's ability to use insulin. This makes you more likely to gain weight and develop type 2 diabetes, even if your diet and exercise habits haven't changed. Fixing sleep continuity is a key metabolic intervention.

Combined oral contraceptive pills (COCP) are the first-line pharmacological management for menstrual irregularity and hyperandrogenism in women with PCOS.

If you have irregular periods or signs of high androgens (like hirsutism), combined oral contraceptives are the recommended first medication. Low-dose versions are preferred.

SGLT2 inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin) lower blood glucose through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, providing modest weight loss and blood pressure reduction.

SGLT2 inhibitors are oral medications that help your kidneys remove sugar from your body through urine. This lowers blood sugar without relying on insulin, making them useful even in advanced diabetes. They also help with weight and blood pressure. Watch for signs of urinary or genital infections.